Electrochemotherapy, a local treatment for squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa.
Epidermolysis Bullosa (EB) is a rare group of diseases caused by genetic variants in skin structural proteins. EB is characterized by varying degrees of skin fragility, blisters and impaired wound healing, and is classified based on the ultrastructural levels of skin cleavage-simplex, junctional, dystrophic, and Kindler Syndrome. Squamous cell carcinoma (SCC) is the most severe complication and most common cause of death of patients with EB, particularly in those with recessive dystrophic Epidermolysis Bullosa (RDEB). To date, the first line of treatment of SCC in patients with RDEB is surgery, despite the high risk of recurrence. Radiotherapy and systemic therapy have been avoided due to its skin toxicity. Recently, electrochemotherapy (ECT) has been proposed as a potential treatment. We report eight sessions of ECT using bleomycin for treatment of SCC in five patients with EB. After 8 weeks all patients showed an objective response. Four patients (seven ECT sessions) had a complete response. The treatment was well tolerated, with mild adverse effects, such as local pain, erythema, and ulceration. Our results demonstrate that ECT is a potential treatment for SCC in patients with RDEB.
['Bartolo|Joana|J|0000-0003-3299-6095', 'Farricha|Victor|V|0000-0002-3646-7011', 'Carvalhal|Sara|S|0000-0002-0867-5876', 'Moura|Cecília|C|0000-0001-6968-1447', 'Abecasis|Nuno|N|']
D002294:Carcinoma, Squamous Cell D053672:Electrochemotherapy D004820:Epidermolysis Bullosa D016108:Epidermolysis Bullosa Dystrophica D006801:Humans D009364:Neoplasm Recurrence, Local
chemotherapy electroporation genodermatoses non-melanoma skin cancer